» Articles » PMID: 10584665

Excessive Daytime Sleepiness and Sleep Benefit in Parkinson's Disease: a Community-based Study

Overview
Journal Mov Disord
Date 1999 Dec 10
PMID 10584665
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to investigate the frequency of excessive daytime sleepiness (EDS) and the beneficial effect of sleep on motor performance in an unselected community-based sample of patients with Parkinson's disease (PD). Furthermore, we wanted to identify possible risk factors to these phenomena. Detailed information on somnolence and sleep during daytime, as well as sleep benefit (SB) on awakening, was collected through a questionnaire among 245 patients with PD. Daytime somnolence was graded in groups of no somnolence, mild daytime sleepiness, and EDS. In addition, the occurrence of somnolence in the patients with PD was compared with the occurrence among control groups of patients with diabetes mellitus and of healthy elderly subjects. The correlations between EDS and SB and various motor- and non-motor symptoms of PD were evaluated. Among the patients with PD, 15.5% experienced EDS, significantly more than in the patients with diabetes mellitus (4%) and the healthy control subjects (1%). The frequency of mild daytime sleepiness was similar (10%) in patients with PD and control subjects. The patients with EDS had significantly higher staging of PD, were more disabled, and showed a higher frequency of cognitive decline compared with the patients without somnolence. They also had been using levodopa for a longer time and had more hallucinations. The occurrence of nocturnal sleeping problems and the use of sleeping pills was similar in the two groups, as was the mean age at examination, duration of PD, and presence of fluctuations and dyskinesias. SB was found in 42.2% of the patients with PD. These patients had been using levodopa for significantly longer and had significantly more fluctuations and dyskinesias compared with the patients without SB. Our results suggest that mild daytime sleepiness may be a result of normal aging, whereas more severe EDS can be explained by the neuropathologic changes of PD. The data from this community-based study confirms the previously reported high frequencies of SB.

Citing Articles

Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trial.

Feigl B, Lewis S, Burr L, Schweitzer D, Gnyawali S, Vagenas D EClinicalMedicine. 2024; 69:102474.

PMID: 38361993 PMC: 10867415. DOI: 10.1016/j.eclinm.2024.102474.


REM Sleep Loss-Induced Elevated Noradrenaline Plays a Significant Role in Neurodegeneration: Synthesis of Findings to Propose a Possible Mechanism of Action from Molecule to Patho-Physiological Changes.

Giri S, Mehta R, Mallick B Brain Sci. 2024; 14(1).

PMID: 38275513 PMC: 10813190. DOI: 10.3390/brainsci14010008.


REM Sleep Behavior Disorder and Cognitive Functions in Parkinson's Patients: A Systematic Review.

Marafioti G, Corallo F, Cardile D, Di Lorenzo G, Quartarone A, Lo Buono V J Clin Med. 2023; 12(23).

PMID: 38068449 PMC: 10707147. DOI: 10.3390/jcm12237397.


Significant potential of melatonin therapy in Parkinson's disease - a meta-analysis of randomized controlled trials.

Iftikhar S, Sameer H, Zainab Front Neurol. 2023; 14:1265789.

PMID: 37881313 PMC: 10597669. DOI: 10.3389/fneur.2023.1265789.


Severity of Daytime Sleepiness and Parkinsonian-Like Symptoms in Korean Adults Aged 50-64 Years.

Shin C, Kim R, Thomas R, Yun C, Lee S, Abbott R J Clin Neurol. 2022; 18(1):33-40.

PMID: 35021274 PMC: 8762500. DOI: 10.3988/jcn.2022.18.1.33.